ROCHE PHARMA, S.A. secures contract for Antineoplastic agents - Supply of human use medicines that contain the following active ingredients: vemurafenib, alpha dornsa, vismodegib, cobimetinib, alectinib, emicizumab, poatuzumab, pertuzumab/trastuzumab, risdiplam, faricimab, entrectinib and satrizumab through the negotiated procedure without advertising without advertising

Spain, Aug. 28 -- Spain based ROCHE PHARMA, S.A. has secured contract from Direccion General de Gestion Economica, Contratacion e Infraestructuras de la Conselleria de Sanidad for Antineoplastic agents - Supply of human use medicines that contain the following active ingredients: vemurafenib, alpha dornsa, vismodegib, cobimetinib, alectinib, emicizumab, poatuzumab, pertuzumab/trastuzumab, risdiplam, faricimab, entrectinib and satrizumab through the negotiated procedure without advertising without advertising. The value of the contract is worth 3744262167 EUR.

Published by HT Digital Content Services with permission from Pivotal Sources....